Geschäftsbericht der Lindenhofgruppe 2019

Thema Fachgebiet Ansprechperson Lindenhofgruppe Kooperations- partner /  Sponsor Ist ein einziger Calprotectinwert aussagekräftig für einen zuverlässigen bzw. adäquaten Therapieentscheid? Gastroenterologie PD Dr. med. Peter Netzer MCL Medizinische Laboratorien Diagnostik der Laktoseintoleranz per Biopsie-basiertem Laktase-Schnelltest im klinischen Alltag Gastroenterologie PD Dr. med. Peter Netzer – Erfassung der mittels ESD-Technik resezierten Tumoren im Gastrointestinaltrakt in den letzten 10 Jahren. Wie ist die Erfolgsrate? Welche Tumoren lassen sich mittels ESD behandeln? Komplikationsrate? Gastroenterologie PD Dr. med. Peter Netzer – Audit of colon polyps surveillance programme in daily clinical practice Gastroenterologie PD Dr. med. Peter Netzer – Combined Phase 2b / 3, Double-Blind, Randomized, Placebo- Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Ulcerative Colitis (Gilead_GS-US-418-3898_CU) Gastroenterologie Prof. Dr. med. Frank Seibold Gilead A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis (Gilead GS-US-418-3899) Gastroenterologie Prof. Dr. med. Frank Seibold Gilead Combined Phase 3, Double-blind, Randomized, Placebo- Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease (Gilead_GS-US-419-3895_MC) Gastroenterologie Prof. Dr. med. Frank Seibold Gilead A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease (Gilead_GSUS-419-3896_MC_OL) Gastroenterologie Prof. Dr. med. Frank Seibold Gilead Sciences Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study of Oral Ozanimod as Induction and Main- tenance Therapy for Moderately to Severely Active Crohn’s Disease (Ozanimod_RPC01-3201_Induction_MC + Ozani- mod_RPC01-3203_Maintenance_MC) Gastroenterologie Prof. Dr. med. Frank Seibold Celgene ACRE, A Multi-Center, Multi-National, Randomised, Double- Blind, Placebo Controlled, Parallel Group, Phase IIa Study to Evaluate the Efficacy, Safety and Tolerability of an Anthocyanin Rich Extract (ACRE) in Patients with Ulcerative Colitis Gastroenterologie Prof. Dr. med. Frank Seibold Swiss IBDnet 73